Understanding the Ready-to-Use Lyophilized Reagent Workflow
In vitro diagnostics is evolving rapidly, and one of the most persistent operational challenges facing laboratories, clinics, and point-of-care settings is reagent logistics and handling complexity. A ready-to-use lyophilized reagent workflow addresses this challenge directly by eliminating cold chain dependency, reducing manual preparation steps, and shortening the overall testing cycle. Nanjing Poclight Biotechnology Co., Ltd., operating under the brand Poclight Biotechnology, has built its diagnostic reagent portfolio around exactly this principle, offering a practical answer to one of the industry's longest-standing pain points.
Why Ready-to-Use Lyophilized Reagents Matter
Traditional chemiluminescence immunoassay (CLIA) reagents typically require strict cold chain storage, which drives up logistics costs and introduces risk during transport, particularly in remote or resource-limited regions. Poclight's lyophilized spherical beads are engineered to be stable at 2-30°C for 18 months, which removes the need for refrigerated shipping and storage altogether. This design directly translates into a 50% reduction in logistics costs, a figure that matters significantly for distributors and healthcare partners operating across South Asia, Southeast Asia, the Middle East, Africa, and Latin America, where cold chain infrastructure is not always consistent or affordable.
Beyond cost savings, the lyophilized spherical bead format ensures long-term reagent integrity. Because the reagents are freeze-dried into a stable bead structure, they retain their diagnostic performance over extended storage periods without the degradation risks associated with liquid reagents kept outside controlled temperature ranges. For laboratories and clinics operating in remote or resource-limited environments, this storage flexibility is not a convenience, it is often an operational necessity.

How the Workflow Simplifies Clinical Testing
The ready-to-use nature of Poclight's reagent solutions is closely tied to the company's proprietary Chemiluminescence Resonance Energy Transfer (CRET) technology platform. Unlike conventional magnetic bead-based CLIA systems that require washing and separation steps, the CRET-based homogeneous immunoassay method eliminates these intermediate processes entirely. This "no-wash, no-separation" approach results in a 70% reduction in time and expenditure compared to traditional procedures, a benefit that compounds nicely with the ready-to-use reagent format.
In practical terms, this means a technician does not need to perform complex reconstitution, multiple washing cycles, or lengthy incubation adjustments before running a sample. The reagent, already stable and ready for use, pairs directly with Poclight's C5000 Micro-Chemiluminescence Immunoassay Analyzer to deliver results in just 3 to 15 minutes. For emergency departments, ICUs, and primary care settings where time-to-result directly affects patient outcomes, this streamlined workflow represents a meaningful operational advantage.
A Broad and Clinically Relevant Test Menu
The value of a ready-to-use lyophilized reagent workflow is amplified when paired with a comprehensive assay menu. Poclight's reagent portfolio spans more than 50 biomarkers across multiple clinical categories, including:

- Inflammation and infection diagnostics, such as C-Reactive Protein (CRP), Procalcitonin (PCT), Interleukin-6 (IL-6), Serum Amyloid A (SAA), and Heparin Binding Protein (HBP)
- Cardiovascular disease markers, including High-sensitivity Cardiac Troponin T (hs-cTnT), D-Dimer, Creatine Kinase-MB (CK-MB), Myoglobin (MYO), NT-proBNP, and BNP
- Thyroid function panels, covering TSH, TT3, TT4, FT3, and FT4
- Fertility and hormone testing, including AMH, FSH, LH, Estradiol, Progesterone, Prolactin, Testosterone, Cortisol, β-hCG, and Folate
- Diabetes and metabolic testing, such as HbA1c, Insulin, and Ferritin
- Bone metabolism testing with 25-Hydroxy Vitamin D (25-OH VD)
- Tumor marker testing, including PSA, fPSA, CEA, AFP, CA125, CA15-3, CA19-9, and CYFRA21-1
- Respiratory diagnostics such as KL-6 for interstitial lung disease assessment
- Platelet function and coagulation-related testing, including CD41, CD45, CD61, CD42a, CD42b, PAC-1, CD62P, and AA/ADP-induced platelet activation testing
This breadth means that a single ready-to-use reagent platform can support inflammation panels in an ICU, hormone monitoring in a women's health clinic, and cardiac biomarker testing in an emergency chest pain center, all without requiring separate cold chain logistics for each application.
Real-World Application of the Workflow
The practical benefits of this reagent workflow are reflected in several documented use cases. In emergency chest pain centers, the combination of the C5000 analyzer and ready-to-use reagents has supported a substantial reduction in door-to-balloon time through ultra-fast CLIA point-of-care testing. In community health centers, the same workflow has brought CLIA-level sensitivity to primary care settings without requiring large laboratory infrastructure.
In ICU sepsis management, the synergy of PCT and IL-6 testing, enabled by the ready-to-use reagent format, has accelerated clinical decision-making during critical infection response scenarios. Similarly, in decentralized women's care settings, integrating endocrine and fertility monitoring through benchtop CLIA testing has allowed lab-quality results to be delivered directly within clinic environments, without the delays typically associated with sample referral to centralized labs.
Operational and Economic Advantages
Because Poclight's instruments, including the C5000 analyzer, are designed without internal liquid paths, the maintenance-free operation pairs naturally with the ready-to-use reagent workflow. There are no hidden cleaning or consumable costs associated with washing steps, since the homogeneous CRET-based assay method does not require them. This combination of reagent and hardware design supports a pricing approach built around low-cost diagnostic solutions and zero hidden maintenance costs, while also creating high-margin opportunities for distributors who adopt the platform.
Supporting Certifications and Quality Standards
Poclight's reagent and instrument systems operate under ISO 13485 quality management standards, and the company holds CE Certification, NMPA certification, and NGSP certification. These credentials provide a foundation of quality assurance for laboratories and healthcare partners evaluating a ready-to-use lyophilized reagent workflow for adoption.
Conclusion
For healthcare providers, distributors, and laboratory operators seeking to reduce logistics burden, simplify testing procedures, and accelerate turnaround times, the ready-to-use lyophilized reagent workflow developed by Nanjing Poclight Biotechnology Co., Ltd. offers a technically grounded and practically validated solution. By combining room-temperature stable lyophilized spherical beads with the patented CRET technology platform and the compact C5000 analyzer, Poclight Biotechnology addresses the core pain points of cold chain cost, operational complexity, and turnaround delay in a single, integrated diagnostic workflow suited for clinical laboratories, emergency departments, primary care centers, and veterinary diagnostics alike.
www.poclight.com
Nanjing Poclight Biotechnology Co., Ltd
